Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954464 | 0.88 | HSD17B10 (0.66) | CYP2C19CYP1A2CYP2C9HSD17B10KDM4E | |
| SCHEMBL477642 | 0.86 | CYP2C19 (0.58) | CYP2C19CYP1A2CYP2C9HSD17B10KDM4E | |
| SCHEMBL4601854 | 0.85 | PTPN11 (0.53) | CYP2C19CYP1A2CYP2C9MRGPRX4RXFP1 | |
| SCHEMBL983425 | 0.85 | CYP1A2 (0.57) | CYP2C19CYP1A2CYP2C9KDM4EALDH1A1 | |
| SCHEMBL3995376 | 0.84 | RXRB (0.58) | CYP2C19CYP1A2CYP2C9HSD17B10TSHR | |
| SCHEMBL16958277 | 0.84 | CYP2C19 (0.58) | CYP2C19CYP1A2CYP2C9HSD17B10KDM4E | |
| SCHEMBL282980 | 0.84 | CNR2 (0.50) | CYP2C19HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL345774 | 0.82 | KDM4E (0.58) | CYP2C19HSD17B10KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL10978991 | 0.81 | KDM4E (0.56) | CYP2C19HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL4200632 | 0.81 | LRRK2 (0.63) | KDM4EALDH1A1MRGPRX4RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8501794-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8492371-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2411382-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2344463-A2 | 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2010111572-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2219629-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010054024-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2146973-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009048936-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130953-A2 | 2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1940799-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007047676-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PARMEE EMMA R | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | CYP2C19 228/4885CYP1A2 84/4885CYP2C9 337/4885 |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP2C19 707/4885CYP1A2 590/4885CYP2C9 919/4885 |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | CYP2C19 2272/4885CYP1A2 1304/4885CYP2C9 1950/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP2C19 1135/4885CYP1A2 1251/4885CYP2C9 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.